Navigation Links
Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
Date:5/27/2009

t to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2008; and other ri
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets. This popular ticket exchange is ... , Ariana Grande is nearing that next step in the ... considered a superstar in the music and entertainment business, but ... released her second straight No. 1 album, will hit the ...
(Date:9/20/2014)... The print component of “Work-Life Balance” is being ... with a circulation of approximately 97,000 copies and ... is distributed nationally through a vast social media ... sites and partner outlets. To explore the digital ... , The publication features an exclusive Mediaplanet interview ...
(Date:9/20/2014)... -- As flu season approaches, the best way to ... flu shot and a checkup, according to an infectious ... vaccinate people against the flu, and also address other ... may provide flu shots for their customers, but they ... medical director of infection prevention and control for the ...
(Date:9/20/2014)... 2014 New PharmaPoint Drug Evaluation ... to 2023?. The asthma market saw very slow ... become saturated with relatively efficacious standard therapies, such ... corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, ... However, the launch of seven novel targeted biologic ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2
... fluid in the ears does not improve speech, hearing or ... two reasons for ear tube surgery -- persistent, severe ear ... otherwise healthy child. Doctors have been concerned that if surgery ... long-term developmental impairment. ,"We were led to the conclusion ...
... companies to drop a historic case in South Africa ... according to leading non-governmental organizations (NGOs). ,The 39 ... legalized use and import of generic medicines free from ... biggest in the world, had challenged the order on ...
... Researchers in the UK say that wound healing in depressed ... These and related reports find a place in the latest ... have direct and indirect effects on the rate of wound ... have been shown to affect the immune system, which may ...
... J. Keefe of Duke University Medical School in Durham, North ... of the Journal of pain. Patients who use religion or ... can reduce their pain and boost their sense of well ... expect that people coping with chronic illness or chronic pain ...
... exercising reduces the risk of heart disease. But almost everyone ... But recent study shows that skinny people are also prone ... important factors in the genesis of various heart ailments. ... Canada, who headed the study, says that heart disease does ...
... which was developed to fight resistant bacteria, is already ... resistance. ,The drug linezolid is used to treat ... the old standby antibiotic vancomycin. The hope has been ... problem of vancomycin-resistant enterococci infections. But in the April ...
Cached Medicine News:Health News:Researchers urge caution in using ear tube surgery 2Health News:Researchers urge caution in using ear tube surgery 3Health News:India to benefit from pharma companies' move 2
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... (Nasdaq: VRUS ) announced today the pricing ... its common stock at an offering price of $46.33 ... selling 2,300,000 shares and the selling stockholders are selling ... deducting the underwriting discount and estimated offering expenses, of ...
... investor meeting held today in New York, NY, Watson ... update on its Global businesses, including a detailed overview ... Global Generics and Global Brands businesses, and an update ... the meeting, the Company provided its preliminary 2011 financial ...
Cached Medicine Technology:Pharmasset Prices Public Offering of Common Stock 2Pharmasset Prices Public Offering of Common Stock 3Watson Presents Outlook for Continued Long Term Growth 2Watson Presents Outlook for Continued Long Term Growth 3Watson Presents Outlook for Continued Long Term Growth 4Watson Presents Outlook for Continued Long Term Growth 5Watson Presents Outlook for Continued Long Term Growth 6Watson Presents Outlook for Continued Long Term Growth 7Watson Presents Outlook for Continued Long Term Growth 8
Delicate membrane hook/pick with hook on side of instrument for engaging membranes. 20 gauge shaft with balanced titanium handle. Dark finish for reduced glare. Left....
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 150 degrees....
0.2 mm, 90o angled tip. Flat smooth handle with polished finish....
Nucleus manipulator facilitates lens rotation during phacoemulsification....
Medicine Products: